Methylated Septin 9 as a Promising Biomarker in the Diagnosis and Recurrence Monitoring of Colorectal Cancer

Table 3

Relationship between mSEPT9 and pathological characteristics of patients with CRC.

Variables	Total	S9-positive cases	S9-negative cases	value
CRC cases	616	440 (71.4%)	176 (28.6%)
Gender				0.079
Male	397	293 (73.8%)	104 (26.2%)
Female	219	147 (67.1%)	72 (32.9%)
Age				0.137
<60	272	186 (68.4%)	86 (31.6%)
≥60	344	254 (73.8%)	90 (26.2)
Location				0.664
Colon	303	221 (72.9%)	82 (27.1%)
Rectosigmoid transition	12	9 (75%)	3 (25%)
Rectum	301	210 (69.8%)	91 (30.29%)
TNM stage				0.0001
I	91	45 (49.5%)	46 (50.5%)
II	170	128 (75.3%)	42 (24.7%)
III	267	195 (73.0%)	72 (27.0%)
IV	88	72 (81.8%)	16 (18.2%)
T stage				0.0001
T1	38	15 (39.5%)	23 (60.5%)
T2	70	36 (51.4%)	34 (48.6%)
T3	350	267 (76.3%)	83 (23.7%)
T4	158	122 (77.2%)	36 (22.8%)
N stage				0.004
N0	264	177 (67.0%)	87 (33.0%)
N1	156	108 (67.9%)	51 (32.1%)
N2	193	155 (80.3%)	38 (19.7%)
M stage				0.220
M0	528	382 (72.3%)	146 (27.7%)
M1	88	58 (65.9%)	30 (34.1%)
Histological grade				0.836
Low	42	30 (71.4%)	12 (28.6%)
Moderate	560	401 (71.6%)	159 (28.4%)
High	14	9 (64.3%)	5 (35.7%)
Vascular invasion				0.007
Absent	89	59 (66.3%)	30 (33.7%)
Present	410	309 (75.4%)	101 (24.6%)
Unknown	117	72 (61.5%)	45 (38.5%)
Nerve invasion				0.030
Absent	133	97 (72.9%)	36 (27.1%)
Present	366	271 (74.0%)	95 (26.0%)
Unknown	117	72 (61.5%)	45 (38.5%)
Tumor size (cm)				0.0001
<5	351	230 (65.5%)	121 (34.5%)
≥5	265	210 (79.2%)	55 (20.8%)
CEA				0.061
<5	341	254 (74.5%)	87 (25.5%)
≥5	275	186 (67.6%)	89 (32.4%)
CA19-9				0.576
<37	519	373 (71.9%)	146 (28.1%)
≥37	97	67 (69.1%)	30 (30.9%)

S9: methylated septin 9 DNA; CEA: carcinoembryonic antigen; CA19-9: carbohydrate antigen-19-9; CRC: colorectal cancer.